Clinical

Dataset Information

0

A Phase 1,Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors


ABSTRACT: Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.

DISEASE(S): Nsclc,Colorectal Cancer,Pancreatic Cancer,Metastatic Cancer,Neoplasms,Malignant Neoplasms

PROVIDER: 2717701 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2278745 | ecrin-mdr-crc
| 2541477 | ecrin-mdr-crc
| 2537689 | ecrin-mdr-crc
| 2336201 | ecrin-mdr-crc
| 2210462 | ecrin-mdr-crc
2020-07-26 | GSE147537 | GEO
| 2239768 | ecrin-mdr-crc
| PRJNA615206 | ENA
| 2400329 | ecrin-mdr-crc
| 2384438 | ecrin-mdr-crc